DNA and Sagemcom Launch the DNA TV-hubi, an Open Android TVTM hub
DNA TV-hubi, launched last month by DNA, is an Android TV based device for TV and multimedia entertainment, designed and manufactured by Sagemcom, consisting in a 4K UHD set-top box for TV viewing and giving access to thousands of apps through Google Play TM app store.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170911005358/en/
The DNA TV-hubi enables to access all terrestrial channels as well as DNA’s cable channels. Thanks to an embedded dual tuner, users can watch a channel and record another one on an external 1TB hard disk drive. The product can receive HD and 4K UHD contents, and when connected to a 4K TV set, the subscriber watching 4K contents enjoys a crystal clear picture with four times the resolution of Full HD. Last but not least, the set-top box allows to receive the pay-TV channels through a broadband connection, so even when not within the coverage area of DNA’s cable or terrestrial networks.
The device, thanks to its embedded certified Android TV operating system, brings access to thousands of downloadable applications through Google Play, such as YouTubeTM – including for 4K contents – Katsomo, Yle Areena and Ruutu to enjoy the 3 major TV channels in Finland, and hundreds of games. Netflix is also supported and will be available this month. Support of Google CastTM enables screen sharing for contents.
The product is designed and manufactured by Sagemcom, and built around the 4K UHD BCM7252S SoC of Broadcom. Sagemcom also carried out the integration and the certification of Android TV operating system that manages all the applications available on the product, as well as the integration of Netflix and DNA TV application. The device embeds software-based encryption system for pay-TV channels, which allows receiving these contents without any TV cards. Sensitive assets from Android universe are also protected with a cardless DRM system.
“We are proud to introduce with DNA this new 4K Android TV set-top box in Finland, that brings the users an enriched entertainment experience thanks to full set of features and the available apps”, said Olivier Taravel, Deputy Chief Executive Officer of Sagemcom Broadband. “4K UHD set-top boxes are key products for the company, at the forefront of Ultra HD technology. Sagemcom relies on a strategic partnership with Broadcom to propose our customers a full range of always more powerful and innovative 4K STBs, including latest generation of Android TV devices.”
“The unique, ground-breaking set-top box - DNA TV-hubi - is for us, as the leading pay-TV operator in Finland, a great opportunity to offer our pay-TV services to all homes in our country with a single device, either through DNA’s cable, terrestrial or IPTV. Android TV’s Google Play store gives customers instant ability to enjoy hugely popular services such as Netflix and Youtube TM , as well as gaming and Google Cast TM . With 4K UHD we can be sure that DNA’s customers will always enjoy the best viewing experience in Finland,” says Ville Partanen, Director of Product Development at DNA.
A French high-tech group of international dimensions, Sagemcom operates
on the broadband (digital home, set-top boxes, Internet routers,
telephony and multimedia terminals), smart city (smart meter, smart
grid, smart infra, smart sites and smart services), and Internet of
With revenue of around 1.6 billion euros, Sagemcom employs 4000 people on five continents and ships every year more than 25 million terminals. Sagemcom aims to remain a world leader in communicating terminals with high added value.
DNA Plc is a Finnish telecommunications group providing high-quality voice, data and TV services for communication, entertainment and working. DNA is Finland's largest cable operator and the leading pay TV provider in both cable and terrestrial networks. For DNA, the key area for growth in corporate business is the new way of working, independent of time and place, facilitated by smart terminal devices, diverse communications services and rapid connections. In 2016, DNA recorded net sales of EUR 859 million and an operating profit of EUR 91 million. DNA has more than 3.8 million subscriptions in its fixed and mobile communications networks. The Group also includes DNA Store, Finland's largest retail chain selling mobile phones. DNA shares are listed on Nasdaq Helsinki Ltd. For further information, visit www.dna.fi or follow us on Twitter @DNA_fi, @DNA_Business and @DNA_Palvelu and Facebook.
Android TV, Google Play, YouTube and Google Cast are trademarks of Google, Inc.
DNA, DNA TV and DNA TV Hubi are registered trademarks of DNA Plc.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31 | Pressemelding
Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00 | Pressemelding
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20 | Pressemelding
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11 | Pressemelding
The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other
Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20 | Pressemelding
Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to
Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31 | Pressemelding
Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom